

# The role of the pharmacist in the management of type 2 diabetes: current insights and future directions

Jeffery David Hughes<sup>1</sup>  
Yosi Wibowo<sup>2</sup>  
Bruce Sunderland<sup>1</sup>  
Kreshnik Hoti<sup>1,3</sup>

<sup>1</sup>School of Pharmacy, Curtin University, Perth, WA, Australia;

<sup>2</sup>Centre for Medicines Information and Pharmaceutical Care (CMIPIC), Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia;

<sup>3</sup>Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo

**Abstract:** Type 2 diabetes is a chronic disease occurring in ever increasing numbers worldwide. It contributes significantly to the cost of health globally; however, its management remains in the most part less than optimal. Patients must be empowered to self-manage their disease, and they do this in partnership with health care professionals. Whilst the traditional role of the pharmacist has been centered around the supply of medicines and patient counseling, there is an evergrowing body of evidence that pharmacists, through a range of extended services, may contribute positively to the clinical and humanistic outcomes of those with diabetes. Further, these services can be delivered cost-effectively. This paper provides a review of the current evidence supporting the role of pharmacists in diabetes care, whilst providing a commentary of the future roles of pharmacists in this area.

**Keywords:** pharmacy, interventions, outcomes, benefits, glycemic control, cost-effectiveness

## Introduction

Diabetes mellitus (“diabetes”) is one of the fastest growing chronic diseases worldwide, and is associated with significant morbidity, mortality, and health care costs. Diabetes is characterized by high levels of glucose in the blood (hyperglycemia). There are three main types of diabetes:

- Type 1 diabetes mellitus (T1DM) in which there is an absolute deficiency in insulin production. This disease can occur at any age, although it mostly occurs in children and young adults.<sup>1</sup>
- Type 2 diabetes mellitus (T2DM) which is associated with insulin resistance, with an initial increase in insulin secretion, however over time, beta cell death and insulin insufficiency. Although T2DM mainly occurs in people aged over 40 years old, the disease is also becoming increasingly prevalent in the younger age group.<sup>2,3</sup>
- Gestational diabetes which occurs during pregnancy. The condition usually disappears once the baby is born; however, a history of gestational diabetes increases a woman’s risk of developing T2DM later in life.<sup>1</sup>

The statistics related to diabetes mellitus globally are alarming. The International Diabetes Federation (IDF) Diabetes Atlas, Seventh Edition, 2015, provides the following estimates: one in 11 adults have diabetes (416 million), nearly half (46.5%) of adults with diabetes are undiagnosed, one in seven births are affected by gestational diabetes, 542,000 children have type 1 diabetes, and a person dies from diabetes every 6 seconds.<sup>4</sup> Further, the IDF estimates that by 2040, one in 10 adults (642 million) will have diabetes.<sup>4</sup>

Correspondence: Jeffery David Hughes  
School of Pharmacy, Curtin University,  
GPO Box U1987, Perth, WA 6845,  
Australia  
Email J.D.Hughes@curtin.edu.au

Of those people with diabetes, three quarters (75%) live in low- and middle-income countries.<sup>4</sup> The Western Pacific region (which includes Australia) has 37% of all adults living with diabetes. This includes 100 million people in the People's Republic of China (ranked highest in number of people with diabetes), 10 million people in Indonesia (seventh highest), and 7.2 million in Japan (ninth highest). Also included in this region is the country with the highest prevalence of diabetes the Pacific Island nation of Tokelau where 30% of the adult population has diabetes. Globally, Cambodia has the lowest prevalence of diabetes at 3%.<sup>4</sup>

T2DM is the greatest contributor to the burden of diabetes globally accounting for up to 90% of people with diabetes worldwide.<sup>4</sup> Further, its prevalence is increasing in all countries around the world. This increase has paralleled the global epidemic of obesity. It is estimated that since 1980 worldwide, obesity has nearly doubled. In 2008, it was estimated that there were 1.4 billion adults (35% of those 20 years or older) who were overweight, of which over half a billion (11%) were obese.<sup>5</sup> Importantly, it is reported that being overweight or obese contributes significantly to the burden of diabetes (44%), ischemic heart disease (23%), and certain cancers (range 7%–41%).<sup>5</sup> Yet, obesity is preventable, and strategies to prevent diabetes and cardiovascular disease both include the common goal to optimize peoples' weight through diet and exercise.

Adults with diabetes have a two- to threefold increased risk of suffering a heart attack or stroke compared to those without diabetes.<sup>6</sup> The microvascular complications of diabetes mellitus make it the leading cause of preventable blindness, renal disease, and amputation in developed countries.<sup>6–8</sup> These complications have dramatic implications for health care costs, with the total annual cost impact of diabetes in Australia estimated to be at \$14.6 billion,<sup>9</sup> whilst globally, it is estimated to account for 12% of the global health expenditure (US\$673 billion).<sup>4</sup> By 2040, it is estimated that the proportion of global health expenditure will exceed US\$802 billion.<sup>4</sup>

Optimizing therapy in patients with diabetes is a difficult clinical task requiring considerable patient education and motivation. The goal is to improve glycemic control without adverse bodyweight gain or hypoglycemia, and with a positive or neutral effect on lipid levels and blood pressure. Proper drug selection involves identifying the drug that is most likely to improve control and least likely to cause interactions, and adverse effect or adherence problems. Consequently, it has the potential to change patients' futures and health care systems' costs.<sup>10</sup>


Pharmacists represent the third largest health profession in the world<sup>11</sup> after doctors and nurses. Most pharmacists work in the community with a smaller proportion in hospital pharmacy, academia, industry, and research. Community pharmacies provide a range of products (in respect to diabetes prescription and nonprescription medication, blood glucose meters and testing strips, needles and swabs, dietary supplements) and services (such as medication review, vaccination, unit dose dispensing, needle exchange, point of care testing, disposal of unwanted medicines, etc).<sup>12</sup> Community pharmacists are considered to be the most accessible health care professionals, as no appointments are required to see them, and to have the highest level of patient contact. As such, they are well placed to play a significant role in the care of patients with T2DM.

This review discusses the health care requirements of T2DM and the current and future roles of pharmacists in its management. For the purposes of the review, papers were identified from English language PubMed and ScienceDirect databases up until October 2016, and by manually reviewing the references for the papers adjudged relevant based on title and abstract, and then full paper review. The keywords used included diabetes, pharmacist, pharmacy, intervention, glycosylated hemoglobin (HbA1c), improvement, benefit, and outcomes. Papers critiqued in this review include original research papers, together with systematic reviews and meta-analyses. The paper aims to provide an overview of the current evidence for the role of pharmacists in diabetes care and insights into what roles pharmacists may fulfill in the future.

## Health care for T2DM patients

The management of those with T2DM should be seen as a partnership between the patient and health care professionals, in which the latter support the former in self-managing his or her disease. Management of every patient should commence with a detailed assessment at the initial diagnosis including an appraisal of diabetes complications and risk factors for complications. This provides the basis for continuing care that includes a treatment plan, treatment administration, monitoring, and review (Figure 1 and Table 1).<sup>1,13–16</sup>

Pharmaceutical care is defined as “the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life”.<sup>17</sup> It provides a platform for multidisciplinary collaboration, which means that the pharmacist and the doctor (and potentially other care providers) join forces to decide on the optimal treatment of the patient so as to achieve the outcome the patient desires.<sup>18</sup> It requires that a professional relationship



**Figure 1** Model of care for T2DM in primary care.

**Note:** Data from references 1 and 13–15.

**Abbreviation:** T2DM, type 2 diabetes mellitus.

between the pharmacist and the patient is established and maintained, and records on patient's medications and other specific information are collected and evaluated. In the case of prescription medicines, a therapy plan currently needs to be developed involving the doctor and the patient;<sup>18</sup> however, pharmacists may also provide input here.

## Pharmacy-based services for T2DM patients

T2DM is one of a number of common complex conditions, including asthma, chronic obstructive pulmonary disease and heart failure, which require more time and expertise than

one practitioner can reasonably provide to achieve optimal therapeutic outcomes for the patient.<sup>1,14</sup> With the development of the concept of pharmaceutical care in which pharmacists are engaged more widely in patient care,<sup>18</sup> the opportunity exists for pharmacists to have a greater role in the care of patients with T2DM.

## Evidence of the benefits of pharmacists in the care of T2DM patients

Extensive studies worldwide have evaluated the effectiveness of pharmacy-based interventions in supporting people

**Table 1** Processes involved in the care of patients with T2DM

Stage	Activity	Component
Initial assessment	History taking	Specific symptoms of glycosuria/hyperglycemic Predisposition to diabetes, eg, age, family history, obesity, lifestyle issues (eg, smoking, diet, alcohol, physical activity, occupation) Risk factors for complications: personal or family history of cardiovascular disease, overweight/obesity, smoking, hypertension, dyslipidemia Symptoms of complications, eg, cardiovascular symptoms, neurological symptoms, renal problems, foot and eye problems Other medical conditions Medications (if any) Education (if any) Psychosocial status, eg, attitudes about illness, expectations, resources – financial, social, and emotional
	Physical examinations	Weight/waist: BMI, waist circumference Cardiovascular system, eg, blood pressure measurement Eyes, eg, pupil dilation Feet, eg, skin condition, sensation Peripheral nerves, eg, sensation Urinalysis, eg, albumin
	Laboratory evaluation	Glycemia: HbA1c, BGL Lipids: LDL-C, HDL-C, total cholesterol, triglycerides Renal function: plasma creatinine (eGFR), albuminuria Other tests when necessary
Treatment plan	Individualized treatment targets	Glycemic control: BGL, HbA1c Control of risk factors for complications: lipids, blood pressure, BMI, cigarette consumption Urinary albumin excretion Physical activity
	Development of treatment plans	Antidiabetic medications Diet Physical activity Prevention/treatment of complications
	Patient education	Diabetes disease process Treatment targets Treatment plan Antidiabetic medicines: dosing instructions, use of insulin devices, storage requirements, special precautions, and common/important adverse effects Exercise Diet Prevention/treatment of complications, eg, foot care, smoking cessation, medications for high lipid/blood pressure levels Monitoring SMBG (using glucose meter and interpreting the results) Need for regular medical monitoring
Treatment administration	Medications prepared	Dispensed in accordance with legal requirements
	Appropriate instructions provided	Prescription labels on directions for use Ancillary labels (if required)
Monitoring	Monitor compliance to treatment plans	Medications Exercise plan Diet plan Prevention/treatment plans for chronic complications Scheduled medical monitoring
	Monitor treatment outcomes	Glycemic control: HbA1c, BGL, SMBG Control of risk factors for complications: lipids, blood pressure, BMI, cigarette consumption Presence of complications: cardiovascular system, peripheral nerves, renal, eyes, feet
	Monitor adverse effects	Presence of adverse drug effects
Review	Review of treatment plan based on monitoring results	Consider treatment plan adjustment Consider education adjustment Referral

**Note:** Data from references 1 and 13–15.

**Abbreviations:** BGL, blood glucose level; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SMBG, self-monitoring of blood glucose; T2DM, type 2 diabetes mellitus.

with T2DM. Most of the studies have been conducted in developed western countries, particularly the United States of America,<sup>19–22</sup> although examples can be found around the globe including the United Arab Emirates<sup>23</sup> and Hong Kong.<sup>24</sup> Fewer studies however have been conducted in low- and middle-income countries such as Nigeria,<sup>25</sup> Iran,<sup>26</sup> India,<sup>27,28</sup> Brazil,<sup>29</sup> Thailand,<sup>30</sup> Jordan,<sup>31</sup> Iraq,<sup>32</sup> and Malaysia.<sup>33</sup> The range of interventions evaluated are indicated in Table 2.

The interventions were measured for their effectiveness using the following:

- clinical outcomes, such as glycemic control,<sup>29,34–43</sup> reduction of risk factors (such as blood pressure, lipids, and body mass index [BMI]),<sup>29,35,42–44</sup> medication adherence,<sup>34,38,44–46</sup> screening for complications,<sup>43</sup> and drug-related problems identified/solved,<sup>35,37,38,42,45</sup>
- humanistic/social outcomes, such as quality of life,<sup>27,35,36,42,47</sup> satisfaction,<sup>42,46</sup> belief,<sup>45</sup> knowledge,<sup>27,37,38,41,42</sup> lifestyle changes,<sup>44</sup> and self-care activity,<sup>47</sup>
- economic outcomes, such as health costs.<sup>42,43</sup>

**Table 2** Components of pharmacist interventions evaluated in T2DM

Stage	Intervention	Component
Treatment plan/review	Medication review	Medication review <sup>27,34–36</sup>
		Interventions based on patient outcomes (pharmacotherapy follow-up) <sup>29,37–41</sup>
Patient education	Patient education/consultation	Disease process <sup>27</sup>
		Goal setting <sup>42</sup>
		Lifestyle: physical activity, diet <sup>27,42,43</sup>
		Medication <sup>27,34,35</sup>
		Psychosocial support: patient health beliefs <sup>34,35</sup>
Monitoring	Monitoring treatment outcomes	SMBG: blood glucose meters <sup>42</sup>
		Prevention/treatment of complications: foot care, smoking cessation, hypertension, dyslipidemia <sup>43</sup>
		Unspecified <sup>42,44,45</sup> /customized content (ie, education program tailored to patient's prior knowledge) <sup>46</sup>
		Patient self-management services
		Review of blood glucose results <sup>36,37,42</sup>
Monitoring compliance	Monitoring compliance	Physical examination (blood pressure, weight, feet, skin) <sup>42</sup>
		HbA1c measurement <sup>44</sup>
Other	Partnership with other health professionals	Adherence questionnaire <sup>45</sup>
		Liaison with the prescribing doctor <sup>35,42</sup>
		Referral for patient education <sup>42,44</sup>
		Referral to a specialist nurse <sup>44</sup>
		Referral for medical advice <sup>35,37,44</sup>

**Abbreviations:** HbA1c, glycosylated hemoglobin; SMBG, self-monitoring of blood glucose; T2DM, type 2 diabetes mellitus.

Blenkinsopp and Hassey<sup>48</sup> undertook a systematic review to evaluate the effect of community pharmacy interventions in diabetes (types 1 and 2). They reviewed seven papers, three focused on glycemic control, two on adherence, and one each on patient knowledge and medication problems. Six of the studies demonstrated positive results (Table 3), with two being significant. Components of community pharmacy-based interventions which appeared to contribute to effectiveness included the following: patient education/consultation about their diabetes and its treatment, medications, and lifestyle changes; and monitoring/reviewing glycemic control.<sup>48</sup> Since that review, there have been several others which are summarized in Table 3. These systematic reviews have covered the impact of pharmacists in a number of settings from hospitals, outpatients clinics, primary (community) health centers, and community pharmacy.<sup>19–21,49–51</sup> The results of all of the systematic reviews demonstrate support for the role of pharmacist in diabetes care across the various settings.

Collins et al<sup>21</sup> reported that HbA1c levels decreased by an average of 0.76% based upon results of 14 trials involving 2,073 subjects and fasting blood glucose by an average 1.63 mmol/L based upon results of four trials involving 589 subjects as compared to control subjects. Aguiar et al<sup>19</sup> undertook a meta-analysis of 22 studies which examined the effect of pharmacist interventions on glycemic control in T2DM patients. This analysis demonstrated a statistically and clinically significant reduction in HbA1c of –0.85% (95% confidence interval [CI]: –1.06 to –0.65,  $P < 0.0001$ ). When community pharmacy interventions were compared to other outpatient settings, the effect on HbA1c was similar (–0.65% vs –0.98%,  $P = 0.08$ ). Interestingly, overall, the most significant effect on HbA1c was seen in those studies in which participants' baseline HbA1c was >9%. Further, the benefit derived reduced as the age of the participants increased.<sup>19</sup>

Likewise, the reviews in Table 3 have demonstrated statistically significant improvements in other clinical outcomes such as reduction in risk factors and improved medication adherence. For example, Santschi et al's<sup>20</sup> meta-analysis demonstrated significant reductions in both systolic blood pressure (SBP) (–6.2 mmHg, 95% CI –7.8 to –4.2) and diastolic blood pressure (DBP) (–4.5 mmHg, 95% CI: –6.2 to –2.8). Six of the 14 studies included in the analysis of SBP involved community pharmacies, with three showing significant falls of between –5.6 mmHg and –20.05 mmHg. Of the two community pharmacy based trials included in the same meta-analysis which reported DBP changes, both again demonstrated a positive effect, and one of them was significant (–3.90 mmHg, 95% CI: –7.18 to –0.62).

**Table 3** Summary of systematic reviews of pharmacists' interventions in diabetes care

Study	Study type and search details	Studies reviewed and settings (n)	Studies and participants	Key outcomes		Conclusions and recommendations	
				Interventions	Clinical*		Humanistic
Blenkinsopp and Hassey <sup>48</sup>	Design: systematic review Databases: National Research Register, Cochrane Library, Current-Controlled Trials, National Electronic Library for Health, Medical Sumssearch, Medline, IPA, CINAHL, Amed, PsychINFO, Prodigy, Clinical Evidence, Electronic Medicines Compendium, Diabetes UK, Postgraduate Medicine Patient Notes, NHS Direct, Surgery Door, Patient UK, and Hand searches of non-indexed Medicus journals and conference proceedings Search dates: 1990–2003	Studies: RCT; controlled (1), effect of community pharmacy intervention in diabetes (T1DM or T2DM) (6) Settings: community pharmacy (7)	Total studies: 7 Total participants: 920	Various: clinical review (clinical assessment, goal setting and monitoring), referrals, HbA1c monitoring and feedback, pharmacist-/nurse-led education sessions, adherence service (centered around health beliefs, lifestyle, adverse effects, rationalizing therapy), identification/resolution of DRPs	HbA1c: 60% vs 40% controlled, -0.3% (2/7 studies) BG: -19.3 mg/dL [-1.07 mmol/L] (1/7) Medication problems: reduction in concerns/misbeliefs about medications Adherence: no change to significant improvement (2/7)	Patient knowledge: significant improvement in T2DM patients (1/7 studies)  Cost-effectiveness: savings from reduced use of other health services and changes in medication outweighed the additional costs of providing the community pharmacy-based consultation service (1/7 studies)	Evidence that community pharmacy interventions to improve diabetes care show promise, but require further evaluation
Wubben and Vivian <sup>51</sup>	Design: systematic review Databases: MEDLINE (1966), CINAHL (1937); Web of Science (1970); IPA (1970); and Cochrane Library Search dates: start dates shown in parentheses to August 2007	Studies: RCTs; controlled clinical trial (9) and cohort studies (1), pharmacist interventions in outpatient setting (11) Settings: clinics (14), community pharmacy (3), community health clinics (2), and community pharmacy/clinic (1)	Total studies: 21 Total participants: 3,981	Various: included: education on lifestyle or diabetes self-care, drug therapy review, case management, monitoring of glycemic control, and adjustment to patients' pharmacotherapy regimen as needed	HbA1c: +0.2% to -2.1% (vs control 18/21 studies) SBP: -0.5 to -18.6 mmHg (n = 12/21) DBP: -0 to -17.4 mmHg (n = 12/21) TC: 0 to -39 mg/dL [0 to -1.0 mmol/L] (n = 3/21) LDL: -6 to -15.6 mg/dL [-0.16 to -0.40 mmol/L] (n = 5/21) HDL: +1.95 to -4.3 mg/dL [+0.05 to -0.11 mmol/L] (n = 4/21) TG: -13.0 to -53.4 mg/dL [-0.15 to -0.60 mmol/L] (n = 4/21)	NR  Cost effectiveness: potentially cost effective based on labor resources and costs to deliver DSM service (n = 1/21), service cost to product significant HbA1c reduction (n = 1/21)	Results supportive of a role for pharmacist in diabetes care. Evidence required from prospective studies of the efficacy of pharmacists in improving diabetes outcomes through the provision of self-management education and pharmacologic management. These findings required dissemination beyond the pharmacy profession



Collins et al <sup>21</sup>	Design: systematic review Databases: MEDLINE and Cochrane CENTRAL Search dates: inception to June 2010	Studies: RCT; pharmacist intervention in a diabetic population Settings: clinics (6), hospitals (2), community pharmacy (4), clinic/hospital (1)	Total studies: 14 (12 T2DM only) Total participants: 2,073	Various: two or more of the following components: diabetes education, instruction on diet and exercise, medication counseling and adherence assessment, and adjustment to patients' pharmacotherapy regimen as needed	HbA1c: -0.76% (vs control; 14 studies, n = 2,073 subjects) FBG: -29.32 mg/dL [-1.62 mmol/L] (4 studies, n = 589 subjects)	NR	NR	Statistically and clinically significant improvement in glycemic control associated with pharmacist interventions. Longer trials trend to greater effect
Omran et al <sup>50</sup>	Design: systematic review Databases: MEDLINE, EMBASE, IPA, CINAHL, and Cochrane Library Search dates: (start date not provided) through to March 12, 2011	Studies: RCT; controlled (6), pharmacist intervention to improve medication adherence in adults with T2DM (2) Settings: clinics (1), hospitals (2), community pharmacy (3), care center (2)	Total studies: 8 (only T2DM) Total participants: 3,930	Various: education-based (individual patient education), behavior-based (unit of use packaging, refill reminders, BGM), affective-based (enhanced communication, regular follow-up, feedback on BG measures) and provider-targeted (improved pharmacist-physician communication) strategies	Adherence: significant improvements in adherence rates (n = 5/8 studies)	NR	NR	Pharmacist intervention generally improve adherence rates, but the impact on clinical outcomes has not been established
Santschi et al <sup>20</sup>	Design: systematic review and meta-analysis Databases: MEDLINE via PubMed (1950 to March 2012), EMBASE (1980 to March 2012), CINAHL (1937 to March 2012), and Cochrane Central Register of Controlled Trials (up to March 2012) Search dates: start date not provided; end dates as given above	Studies: RCTs; impact of pharmacist care on major CVD risk factors among outpatients with diabetes Settings: Outpatient clinics (11) and community pharmacy (4)	Total studies: 15 (12 T2DM only) Total participants: 9,111	Various: 1) medication management (monitoring of drug therapy such as adjustment and change of medications, medication review from patient interviews, or assessment of medication compliance); 2) educational interventions to patients (medications, lifestyle, and physical activity or about compliance); 3) feedback to health care professional (DRPs identification, recommendation and discussion with physician regarding	SBP: WMD -6.2 mmHg [-7.8 to -4.6], P < 0.001 (n = 12/15 studies, 7/12 significant) Studies conducted in community pharmacy greater reduction in SBP (-10.0 mmHg vs -5.5 mmHg) DBP: WMD -4.5 mmHg (-6.2 to -2.8), P < 0.001 (n = 9/15, 3/9 significant) TC: WMD -15.2 mg/dL (-24.7 to -5.7) [-0.39 mmol/L (-0.64 to -0.15)], P = 0.002 (n = 8/15, 2/8 significant) LDL: WMD -11.7 mg/dL (-15.8 to -7.6), [-0.30 mmol/L (-0.41 to -0.20)] P < 0.001 (n = 9/15, 5/9 significant)	NR	NR	Evidence to support pharmacist interventions improve management of major CVD risk factors among outpatients with diabetes. Further research needed to assess which pharmacist interventions are most effective, implementable, and least time-consuming and to demonstrate cost-effectiveness of pharmacist

(Continued)

Table 3 (Continued)

Study	Study type and search details	Studies reviewed and settings (n)	Studies and participants	Interventions	Key outcomes		Conclusions and recommendations
					Clinical	Economic	
Pousinho et al <sup>49</sup>	Design: systematic review Databases: PubMed, Cochrane Central Register of Controlled Trials, and Web of Science Search dates: Inception to January 2015	Studies: RCTs; pharmacist interventions vs usual care in T2DM Settings: community pharmacy (8), primary care clinics (8), hospital clinics (16), and hospitals (4)	Total studies: 36 Total participants: 5,761	medication changes or problems of compliance, development of treatment plans); 4) measurement of CVD risk factors  Various: One or more of the following: counseling and education on diabetes, medication, lifestyle modification, and self-monitoring; reinforcement of medication adherence or complications screening; provision of materials such as educational leaflets and pill boxes; medication review; identification and resolution of drug-related problems; discussions with the primary care provider regarding pharmacotherapy; adjustment of pharmacotherapy; and referrals to other health care professionals	HDL: WMD +0.2 mg/dL (-1.9 to 2.36) [-0.005 mmol/L (-0.049 to 0.061)], <i>P</i> = 0.846 (n = 6/15, 0/6 significant) BMI: WMD -0.9 kg/m <sup>2</sup> [-1.7 to -0.1], <i>P</i> = 0.026 (n = 5/15, 2/5 significant)  HbA1c: -0.18% to -2.1% (vs control 24/26 studies) SBP: -3.3 to -23.05 mmHg (n = 17/18) DBP: -0.21 to -9.1 mmHg (n = 14/15) TC: +18.95 to -32.48 mg/dL [0.49 to -0.84 mmol/L] (n = 10/13) LDL: +7.35 to -30 mg/dL [+0.19 to -0.78 mmol/L] (n = 12/15) HDL: -5.8 to +11 mg/dL [-0.15 to +0.28 mmol/L] (n = 9/12) TG: +12 to -62 mg/dL [0.14 to 0.70 mmol/L] (n = 9/12) BMI: Reduced (n = 12/14) Adherence: Improved (n = 11/13) 10-Year CVD risk: improved (n = 6/6)	Cost effective (n = 3/26 studies)  HRQoL: Improved (n = 11 studies)	interventions in this setting  Need for future studies to look at which elements of pharmacists' interventions contribute to the observed benefits



Aguilar et al <sup>19</sup>	Design: systematic review and meta-analysis Databases: PubMed/MEDLINE, Scopus, and Lilacs Search dates: (start date not provided) up to July 2015	Studies: RCTs; effect of pharmacist interventions on glycemic control Settings: hospital outpatient clinics (15), community pharmacy (8), community based clinics (4) and research center (1)	Total studies: systematic review 30, meta-analysis 22 Total participants: systematic review 4,051, meta-analysis 2,715	Variable: Most involved medication review (n = 25/30). Multifaceted actions to address identified DRPs, including educating patients (concerning diabetes, lifestyle, and self-monitoring) or providing medication counseling (100.0%); sending suggestions or recommendations to the physician regarding changes in medication (46.7%); adjusting pharmacotherapy on the basis of protocols previously established in collaboration with the healthcare team (23.3%); and referring patients to other health professional (eg, dentist) (16.7%)	HbA1c: mean difference -0.85% (95% CI: -1.06, -0.65); $P < 0.0001$ Subgroup analysis: no significant difference in the reduction in HbA1c levels according to the country where the study was conducted, type of contact with the patient, whether a medication review was performed; autonomy of the pharmacist to change drug therapy, provision of support resources, frequency of intervention, and adequate random allocation Outpatient clinic vs community pharmacy: HbA1c effect more pronounced, but not significant (-0.98% vs -0.65%; $P = 0.08$ ) HbA1c benefit: Greater in those with baseline HbA1c > 9.0% (-1.18% vs -0.63%; $P = 0.007$ )	NR	NR	Pharmacist interventions improve glycemic control in patients with type 2 diabetes, benefits appear greater in younger patients or those with higher baseline HbA1c levels
-----------------------------	---	---	---	--	--	----	----	--

**Notes:** <sup>a</sup>The values shown within square brackets [ ] are calculated values in SI units based on the published results. The values shown within parentheses ( ) represent the number of studies reviewed which addressed the outcome (denominator) and the number which showed positive results (numerator).

**Abbreviations:** RCT, randomized controlled trial; T2DM, type 2 diabetes mellitus; DRP, drug related problem; BG, blood glucose; NR, not reported; DSM, disease state management; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; FBG, fasting blood glucose; BGM, blood glucose monitoring; CVD, cardiovascular disease; WMD, weighted mean difference; BMI, body mass index; HRQoL, health-related quality of life; CI, confidence interval; CINAHL, Cumulative Index to Nursing and Allied Health Literature; IPA, International Pharmaceutical Abstracts.

Significant reductions were also reported for total cholesterol, low-density lipoprotein cholesterol, and BMI.

Despite significant variations in the methods by which adherence was measured, pharmacist interventions were generally shown to have a positive effect, although it was unclear in many instances what impact the improvement had on clinical outcomes.<sup>50</sup> Patients' knowledge of their disease and its complications, its treatment (pharmacological and non-pharmacological), and self-monitoring has also been shown to be increased through pharmacist-delivered educational interventions.<sup>51</sup>

The ability to demonstrate improvements in the quality of life of people with diabetes is often hampered by the short duration of the studies, and the tools chosen. Despite these factors, pharmacist-managed interventions again showed positive benefits. Limited studies have investigated the economic benefits of pharmacist interventions in diabetes care. A recent meta-analysis by Wang et al,<sup>22</sup> which included 25 studies, reported that "pharmacist-managed services had a positive return in terms of economic viability". Ten of the 25 studies were completed in community pharmacy. Benefits demonstrated included that the average cost of a 1% reduction in HbA1c was US\$174 per person; such a reduction translates into a 21% reduction in macrovascular complications. Further, whilst pharmacist interventions often increased medication costs, these costs were offset by a reduction in medical costs associated with emergency department attendances and hospitalization.<sup>22</sup> In fact, compared to usual care, pharmacist-led services produced cost savings in the range of US\$8 to \$85,000 per year, whilst costing between US\$62,803 and US\$114,576 to prevent one diabetes-related macrovascular and microvascular event. Of the six studies that included cost-benefit analysis (cost-to-benefit ratio range 1:1–8.5:1), the three that were community pharmacy based were either cost neutral (1:1)<sup>52</sup> or cost effective (6.1:1<sup>53</sup> and 8.5:1<sup>54</sup>). Hendrie et al<sup>55</sup> evaluated the economic benefit of reduced glycemic events (hypo- and hyperglycemia) in a group of patients who enrolled into a 6-month Diabetes Management Education Program (DMEP). They found that the intervention resulted in significantly greater reductions in the number of hyper- and hypoglycemic events relative to the control group (odds ratio [OR] 0.34, 95% CI 0.22–0.52,  $P = 0.001$  vs OR 0.54, 95% CI 0.34–0.86,  $P = 0.009$ ). This reduction translated into a net reduction of 1.86 days with glycemic episodes per patient per month. In terms of cost-effectiveness, the DMEP costs AU\$43 (US\$39) per day of glycemic symptoms avoided relative to standard care.

In summary, to date, pharmacist interventions to improve the care of patients with diabetes, and in particular those with

T2DM, have been shown to deliver positive clinical, humanistic, and economic benefits. However, the interventions, which are often multifaceted, have varied across studies, although often education- and clinical review-based, making it difficult to determine which elements deliver the greatest benefits.

## Future roles for pharmacists in T2DM management

To date, evidence supports pharmacists extending their role in diabetes care from medication supply to cognitive services which aim to assist those with diabetes achieve the best possible clinical outcomes through supporting their self-management. Realistically, pharmacists potentially have a role to play in all facets of the care of T2DM patients as depicted in Figure 1. However, widespread implementation of such services in the future will depend on legislative change, adequate funding (government and nongovernment), professional commitment, interprofessional collaboration, and consumer (patient) acceptance.

The importance of the latter should not be underestimated, with recent work again illustrating that consumers do not perceive community pharmacies as a place to go to get assistance with their diabetes care. Consumers are happy to accept that pharmacists can provide them with medications and counseling; however, they have consistent concerns about the knowledge and competency of pharmacists to provide additional services, and that community pharmacies are a suitable environment to deliver them.<sup>56</sup> The findings of Dhippayom and Krass<sup>57</sup> support this, with participants in their study highlighting the main role of pharmacists is medication provision, with some enhancements in supporting adherence and continuity of supply. Therefore, for community pharmacy-based services to succeed, these perceptions must be changed; this will require action from within the pharmacy profession through further training, establishment of private consulting areas, changes to workflows, and proactively promoting pharmacists' capability to deliver enhanced diabetes care.

Delivery of such services within other settings such as hospitals, outpatient clinics, and community-based clinics is likely to be better received by patients, with pharmacists being seen more as a care provider than a supplier of medicines. Evidence supports pharmacists working in these settings, either directing care or collaborating in care.<sup>20</sup>

Targeting of services to those at greatest need would seem appropriate, such as patients with newly diagnosed diabetes<sup>56</sup> who are often overwhelmed by the diagnosis and have a poor understanding of its management. For example, general practitioners often fail to provide adequate education

for patients starting oral hypoglycemics, and community pharmacists are well placed to fulfill this role. Further, the evidence suggests that patients with poorly managed diabetes, that is, those with HbA1c > 9 mmol/L,<sup>19</sup> gain the greatest benefit from pharmacist interventions, suggesting targeting such patients would be appropriate. This could be facilitated through referrals from medical practitioners or pharmacists ordering of HbA1c levels or point-of-care testing.

Funding to deliver pharmacy-based cognitive services is a contentious issue, and whilst they can be funded through a user-pays model, government-funded or third-party payer models are likely to be needed for widespread implementation of such services. For example, depending on the level of remuneration, one would envisage that a limited number of community pharmacies specializing in diabetes would offer extended services. Legislative change to allow pharmacists to manage patients' diabetes therapy either in consultation with their primary health provider or independently, which has occurred in some jurisdictions, will allow pharmacists delivering such services to have greater impact.

Diabetes screening is another area of significant need which pharmacists should engage in as many people living with the disease are undiagnosed. A large-scale trial is about to commence in Australia to evaluate community pharmacists' role in diabetes screening. This study builds upon the work of Krass et al,<sup>58</sup> which demonstrated that a sequential screening program, that is, tick test followed by capillary blood glucose testing, was an effective means to detect prediabetic and diabetic patients.

## Conclusion

There is significant evidence to support the role of pharmacists in providing a range of extended diabetes care services, from the screening to ongoing disease state management. However, despite this, the provision of such services generally remains limited and inconsistent. However, this is set to change, as the number of people with T2DM grows, and the capacity of traditional care providers to cope with these people diminishes. Governments, third-party payers, and consumers will all be looking for cost-effective ways to manage diabetes. Pharmacists are ideally placed to assist patients with their diabetes management within a range of clinical settings as demonstrated by current evidence. Needed now are models of practice which are evidence based, consistent, and scalable, such that they deliver the outcomes desired by all stakeholders.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. American Diabetes Association. Standards of medical care in diabetes - 2013. *Diabetes Care*. 2013;36(Suppl 1):S11–S66.
2. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescent. *J Pediatr*. 2005;146(5):693–700.
3. American Diabetes Association. Type 2 diabetes in children and adolescents. *Diabetes Care*. 2000;23(3):381–389.
4. International Diabetes Federation. IDF Diabetes Atlas, Seventh Edition, 2015. Available from: [www.diabetesatlas.org](http://www.diabetesatlas.org). Accessed October 28, 2016.
5. World Health Organization. Obesity and overweight. Fact sheet [updated June 2016]. Available from: <http://www.who.int/mediacentre/factsheets/fs311/en/>. Accessed October 28, 2016.
6. World Health Organization. Diabetes. Fact sheet [reviewed November 2016]. Available from: <http://www.who.int/mediacentre/factsheets/fs312/en/>. Accessed November 27, 2016.
7. Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clin Diabetes*. 2008;26(2):77–82.
8. Kocer I, Resinkoff S. Visual impairment and blindness in Europe and their prevention. *Br J Ophthalmol*. 2002;86(7):716–722.
9. Diabetes Australia. Diabetes in Australia. 2015. Available from: <https://www.diabetesaustralia.com.au/diabetes-in-australia>. Accessed October 28, 2016.
10. Chloe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by clinical pharmacist: a randomized controlled trial. *Am J Manag Care*. 2005;11(4):253–260.
11. FIP.org. Global pharmacy workforce and migration report: a call for action. 2016. Available from: <https://www.fip.org/files/fip/publications/PharmacyWorkforceMigration.pdf>. Accessed October 28, 2016.
12. OECD.org. Health at a glance 2015. 2015. Available from: <http://www.oecd.org/els/health-systems/health-at-a-glance-19991312.htm>. Accessed October 28, 2016.
13. The Royal Australian College of General Practitioners. *General Practice Management of Type 2 Diabetes: 2016–18*. East Melbourne, Vic: RACGP; 2016. Available from: <https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf>. Accessed December 22, 2016.
14. Indonesian Society of Endocrinology. *Consensus on the Management and Prevention of Type 2 DM in Indonesia*. Jakarta: Indonesian Society of Endocrinology; 2011.
15. Power A, Douglas E, McGregor A, Hudson S. Professional development of pharmaceutical care in type 2 diabetes mellitus: a multidisciplinary conceptual model. *Int J Pharm Pract*. 2006;14(4):289–299.
16. Department of Health, WA, Australia. *Diabetes Model of Care*. Perth: Health Networks Branch, Department of Health, WA, Australia; 2008. Available from: [http://www.healthnetworks.health.wa.gov.au/model-sofcare/docs/Diabetes\\_Model\\_of\\_Care.pdf](http://www.healthnetworks.health.wa.gov.au/model-sofcare/docs/Diabetes_Model_of_Care.pdf). Accessed November 27, 2016.
17. Helper CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp Pharm*. 1990;47(3):533–543.
18. Berenguer B, La Casa C, de la Matta M, Martin-Calero MJ. Pharmaceutical care: past, present and future. *Curr Pharm Des*. 2004;10(31):3931–3946.
19. Aguiar PM, Brito Gde C, Lima Tde M, Santos AP, Lyra DP Jr, Storpirtis S. Investigating sources of heterogeneity in randomized controlled trials of the effects of pharmacist interventions on glycemic control in type 2 diabetic patients: a systematic review and meta-analysis. *PLoS One*. 2016;11(3):e0150999.
20. Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Care*. 2012;35(12):2706–2717.
21. Collins C, Limone BL, Schoole JM, Coleman CI. Effect of pharmacist intervention on glycemic control in diabetes. *Diabetes Res Clin Pract*. 2011;92(2):145–152.

22. Wang Y, Yeo QQ, Ko Y. Economic evaluations of pharmacist-managed services in people with diabetes mellitus: a systematic review. *Diabet Med*. 2016;33(4):421–427.
23. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. *Br J Clin Pharmacol*. 2009;67(5):547–557.
24. Chan CW, Siu SC, Wong CK, Lee VW. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. *J Cardiovasc Pharmacol Ther*. 2012;17(1):57–64.
25. Adibe MO, Ukwe CV, Aguwa CN. The impact of pharmaceutical care intervention on the quality of life of Nigerian patients receiving treatment for type 2 diabetes. *Value Health Reg Issues*. 2013;2(2):240–247.
26. Farsaei S, Sabzghabae AM, Zargazadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. *J Res Med Sci*. 2011;16(1):43–49.
27. Adepu R, Rasheed A, Nagavi BG. Effect of patient counseling on quality of life in type-2 diabetes mellitus patients in two selected South Indian community pharmacies: a study. *Indian J Pharm Sci*. 2007;69(4):519–524.
28. Venkatesan R, Devi AS, Parasuraman S, Sriram S. Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes. *Perspect Clin Res*. 2012;3(1):26–31.
29. Correr CJ, Melchioris AC, Fernandez-Llimos F, Pontarolo R. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil. *Int J Clin Pharm*. 2011;33(2):273–280.
30. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist's input on glycaemic control and cardiovascular risks in Muslim diabetes. *Prim Care Diabetes*. 2008;2(1):31–37.
31. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. *J Manag Care Pharm*. 2012;18(7):516–526.
32. Mahwi TO, Obied KA. Role of the pharmaceutical care in the management of patients with type 2 diabetes mellitus. *Int J Pharm Sci Res*. 2013;4(4):1363–1369.
33. Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. *Patient Prefer Adherence*. 2014;8:1185–1194.
34. Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy based diabetes monitoring program. *J Am Pharm Assoc (Wash)*. 1999;39(6):791–797.
35. Krass I, Armour CL, Mitchell B, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. *Diabet Med*. 2007;24(6):677–683.
36. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists' diabetes care services. *J Am Pharm Assoc*. 2004;44(4):455–466.
37. Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. *Pharm World Sci*. 2006;28(2):65–72.
38. Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team - a pilot study. *Pharm World Sci*. 2004;26(1):18–25.
39. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. *J Am Pharm Assoc (Wash)*. 2003;43(2):173–184.
40. Bliss EA, Codack H, Boothe J. Diabetes care - an evaluation of a community pharmacy based HbA1c testing service. *Pharm J*. 2001;267:264–266.
41. Swain JH, Macklin R. Individualised diabetes care in a rural community pharmacy. *J Am Pharm Assoc (Wash)*. 2001;41(3):458–461.
42. Hughes J. Final report: Customised education programs for patients with diabetes mellitus - use of structured questionnaires and education modules (DMEP study). Perth: Curtin University of Technology; 2006. Available from: <http://6cpa.com.au/resources/third-agreement/customised-education-programs-for-patients-with-diabetes-mellitus-use-of-structured-questionnaires-and-education-modules/>. Accessed December 21, 2016.
43. Fera T, Bluml BM, Ellis WM, Schaller CW, Garrett DG. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. *J Am Pharm Assoc (2003)*. 2008;48(2):181–190.
44. Pinto SL, Bechtol RA, Partha G. Evaluation of outcomes of a medication therapy management program for patients with diabetes. *J Am Pharm Assoc (2003)*. 2012;52(4):519–523.
45. Krass I, Stephenson S, Thuis U, Hourihan F, Taylor S, Armour C. Increasing adherence to medications through delivery of a disease management service for Type 2 diabetes in community pharmacies. *J Soc Admin Pharm*. 2002;19(6):211.
46. Grant RW, Devita NG, Singer DE, Meigs JB. Improving adherence and reducing medication discrepancies in patients with diabetes. *Ann Pharmacother*. 2003;37(7–8):962–969.
47. Abdulkarem AR, Sackville MA. Changes of some health indicators in patients with type 2 diabetes: a prospective study in three community pharmacies in Sharjah, United Arab Emirates. *Libyan J Med*. 2009;4(1):31–36.
48. Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. *Int J Pharm Pract*. 2005;13(4):231–240.
49. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials. *J Manag Care Spec Pharm*. 2016;22(5):493–515.
50. Omran D, Guirguis LM, Simpson SH. Systematic review of pharmacist interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes. *Can J Diabetes*. 2012;36(5):292–299.
51. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. *Pharmacotherapy*. 2008;28(4):421–436.
52. Petkova VB, Petrova GI. Pilot project for education of patients with type 2 diabetes by pharmacists. *Acta Diabetol*. 2006;43(2):37–42.
53. Bunting BA, Lee G, Knowles G, Lee C, Allen P. The hickory project: controlling healthcare costs and improving outcomes for diabetes using the Asheville project model. *Am Health Drug Benefits*. 2011;4(6):343–350.
54. Wertz D, Hou L, DeVries A, et al. Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertension. *Manag Care*. 2012;21(3):44–54.
55. Hendrie D, Miller TR, Woodman RJ, Hoti K, Hughes J. Cost-effectiveness of reducing glycaemic episodes through community pharmacy management of patients with type 2 diabetes mellitus. *J Prim Prev*. 2014;35(6):439–449.
56. Twigg MJ, Poland F, Bhattacharya D, Desborough JA, Wright DJ. The current and future roles of community pharmacists: views and experiences of patients with type 2 diabetes. *Res Social Adm Pharm*. 2013;9(6):777–789.
57. Dhippayom T, Krass I. Supporting self management of type 2 diabetes: is there a role for the community pharmacist? *Patient Prefer Adherence*. 2015;9:1085–1092.
58. Krass I, Mitchell B, Clarke P, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. *Diabetes Res Clin Pract*. 2007;75(3):339–347.

### Integrated Pharmacy Research and Practice

Dovepress

#### Publish your work in this journal

Integrated Pharmacy Research and Practice is an international, peer-reviewed, open access, online journal, publishing original research, reports, reviews and commentaries on all areas of academic and professional pharmacy practice. This journal aims to represent the academic output of pharmacists and pharmacy practice with particular focus on integrated care. All papers are carefully

peer reviewed to ensure the highest standards as well as ensuring that we are informing and stimulating pharmaceutical professionals. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/integrated-pharmacy-research-and-practice-journal>

**Dovepress**

Integrated Pharmacy  
Research and Practice



**News:**

Dove Medical Press is pleased to announce that the ILCA Annual Conference is being held on 1-4 September 2022 [Read more](#)

[Home](#) | [Journals](#) | [Why publish with us?](#) | [Editorial Policies](#) | [Author Information](#) | [Peer Review Guidelines](#) | [Open Outlook](#) | [COVID-19](#) | [Podcasts](#)
[Back to Journals](#)
**Usage**

5 9 2 4

Monthly downloads/views

**Average Article Statistics**

2 7 Days \*

From submission to first editorial decision.

1 0 Days \*

From editorial acceptance to publication.

\*Business days (Mon-Fri)

**Rejection Rate**

7 5 %


The above percentage of manuscripts have been rejected in the last 12 months.



**About Dove Press**

Open access peer-reviewed scientific and medical journals. [Learn more](#)

**Open Access**

 Dove Medical Press is a member of the OAI. [Learn more](#)

**Reprints**

Bulk reprints for the pharmaceutical industry. [Learn more](#)

**Favored Authors**

We offer real benefits to our authors, including fast-track processing of papers. [Learn more](#)

**Promotional Article Monitoring**

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly. [Learn more](#)

**Social Media**


ESCI (EMERGING SOURCES CITATION INDEX)

**Integrated Pharmacy Research and Practice**

  
Member since 2011  
JAN 2008

[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | [Articles](#)
[Article Publishing Charges](#) | [Aims and Scope](#) | [Call For Papers](#)
**Professor Ling**

Department of Pharmacy, University of Sunderland, United Kingdom

EDITOR IN CHIEF

**Editor-in-Chief: Professor Jonathan Ling**

Professor Jonathan Ling is senior lecturer in the Department of Pharmacy, Health and Wellbeing at the University of Sunderland, and is a member of Fuse - the Centre for Translational Research in Public Health. He trained in psychology at the University of Sheffield and his main research interests are on the impact of drugs on human performance and the public health consequences of this use. In addition to this, he is also engaged in collaborative work examining the role of genetic risk factors in chemotherapy-induced nausea and vomiting and on medicines management in the elderly.



Professor Ling

**Editorial Board**

16 Members

**Dr Arain** PAKISTAN

Mudassar Iqbal Arain, Assistant Professor, Department of Pharmacy Practice, Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan.

**Professor Falcão** PORTUGAL

Amílcar Celta Falcão, Professor, Teaching & Research, University of Coimbra, Portugal

**Professor Fendrick** UNITED STATES

A. Mark Fendrick, MD, Professor, Division of General Medicine, Department of Internal Medicine, School of Medicine; Professor, Health Management & Policy, School of Public Health; Director, Center for Value-Based Insurance Design, University of Michigan, Ann Arbor, Michigan, USA

**Prof. Dr. Gunduz** TURKEY

Ufuk Gündüz, Professor, Department of Biology, Middle East Technical University, Turkey

**Professor Jäger** AUSTRIA

Walter Jäger, Professor and Head of Department of Clinical Pharmacy and Diagnostics, University of Vienna, Austria

**Professor Jouyban** IRAN

Abolghasem Jouyban, Professor of Pharmaceutical Analysis, Tabriz University of Medical Sciences, Tabriz, Iran

**Dr Kheir** UNITED ARAB EMIRATES

Nadir Kheir is Professor of Pharmacy Practice, College of Pharmacy, and Manager of the Student Success Center, Ajman University, UAE. Honorary Senior Lecturer, School of Pharmacy, University of Auckland, New Zealand. Research interests include Pharmaceutica Care, patient-related outcome measures, and pharmacy education and training.

**Professor Lim** AUSTRALIA



Education, Universidad Autónoma de Madrid (UAM), Madrid, Spain

**Mr Mohammad Gayoor Khan** INDIA



Truba Institute of Pharmacy, Bhopal MP (Certified Dual Course Medical Writing and Clinical Research).  
Physis Learning Academy New Delhi.

**Professor Muzzio** UNITED STATES

Fernando J. Muzzio, Director, NSF ERC on Structured Organic Particulate Systems; Distinguished Professor, Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ, USA

**Dr Ortiz** MEXICO



Mario Isidoro Ortiz Ramirez , Professor, Academic Area of Medicine Institute of Health Sciences,  
Universidad Autonoma del Estado de Hidalgo, Pachuca, Mexico

**Dr Todd** UNITED KINGDOM



Adam Todd, Founding Editor-in-Chief, School of Pharmacy, Newcastle University, UK

**Professor Vyas** INDIA



Suresh P Vyas, Professor of Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences,  
Dr. H. S. Gour University, Sagar, India

**Professor Wiebe** CANADA



Leonard I. Wiebe, Professor Emeritus, Faculty of Pharmacy and Pharmaceutical Sciences, and Adjunct  
Professor, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta,  
Edmonton, Canada.

**Dr Yap** SINGAPORE



Dr Kevin Yap, Department of Pharmacy, Singapore General Hospital, Singapore.

[Contact Us](#) • [Privacy Policy](#) • [Associations & Partners](#) • [Testimonials](#) • [Terms & Conditions](#) • [Recommend this site](#) • [Top](#)

© Copyright 2022 • Dove Press Ltd • software development by maffey.com • Web Design by Adhesion

The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ("Informa") whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36

**News:**

Dove Medical Press is pleased to announce that the ILCA Annual Conference is being held on 1-4 September 2022 [Read more](#)

[Home](#) | [Journals](#) | [Why publish with us?](#) | [Editorial Policies](#) | [Author Information](#) | [Peer Review Guidelines](#) | [Open Outlook](#) | [COVID-19](#) | [Podcasts](#)

Back to [Journals](#) > [Integrated Pharmacy Research and Practice](#) > Volume 6

**Usage**

5 | 9 | 2 | 4

Monthly downloads/views

**Average Article Statistics**

2 | 7 | Days \*

From submission to first editorial decision.

1 | 0 | Days \*

From editorial acceptance to publication.

\*Business days (Mon-Fri)

**Rejection Rate**

7 | 5 | %

The above percentage of manuscripts have been rejected in the last 12 months.

7 | 6 | 0 | 9 | 6

Papers Published

[Submit New Manuscript](#)


[Login to view existing manuscript status](#)

[Signup for Journal alerts](#)

**About Dove Press**

Open access peer-reviewed scientific and medical journals. [Learn more](#)

**Open Access**

 Dove Medical Press is a member of the OAI. [Learn more](#)

**Reprints**

Bulk reprints for the pharmaceutical industry. [Learn more](#)

**Favored Authors**

We offer real benefits to our authors, including fast-track processing of papers. [Learn more](#)

**Promoting Article Monitoring**

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly. [Learn more](#)

**Social Media**

 Need help?

ESCI (EMERGING SOURCES CITATION INDEX)

**Integrated Pharmacy Research and Practice**

C O P E  
Member since 2011  
0007208

[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | [Articles](#)

[View all](#) (143) | [Volume 11, 2022](#) (11) | [Volume 10, 2021](#) (15)  
[Volume 9, 2020](#) (24) | [Volume 8, 2019](#) (13) | [Volume 7, 2018](#) (14)  
**Volume 6, 2017** (21) | [Volume 5, 2016](#) (11) | [Volume 4, 2015](#) (19)  
[Volume 3, 2014](#) (9) | [Volume 2, 2013](#) (3) | [Volume 1, 2012](#) (3)

Search Articles

**Archive: Volume 6, 2017**

ORIGINAL RESEARCH 

**Identification of the benefits, enablers and barriers to integrating junior pharmacists into the ward team within one UK-based hospital**

Hung MY, Wright DJ, Blacklock J, Needle RJ  
[Integrated Pharmacy Research and Practice 2017](#), 6:181-190  
 Published Date: **13 November 2017**

ORIGINAL RESEARCH 

**Displaying medication costs on dispensing labels as a strategy to reduce wastage: views of the Welsh general public**

Yemm R, Jones C, Mitoko T  
[Integrated Pharmacy Research and Practice 2017](#), 6:173-180  
 Published Date: **24 October 2017**

REVIEW 

**Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists**

Caballero J, Darsey EH, Walters F, Belden HW  
[Integrated Pharmacy Research and Practice 2017](#), 6:163-171  
 Published Date: **17 October 2017**

ORIGINAL RESEARCH 

**Opinion of pharmacy practitioners toward the Continuing Pharmacy Education program: a study from a tertiary care hospital in central Nepal**

Poudel RS, Piryani RM, Shrestha S, Chaurasiya R, Niure BP  
[Integrated Pharmacy Research and Practice 2017](#), 6:157-161  
 Published Date: **22 September 2017**

ORIGINAL RESEARCH 

**Does an integrated information technology system provide support for community pharmacists undertaking Discharge Medicines Reviews? An exploratory study**

Mantzourani E, Way CM, Hodson KL  
[Integrated Pharmacy Research and Practice 2017](#), 6:145-156  
 Published Date: **20 September 2017**

ORIGINAL RESEARCH 

**The role of community pharmacists in patient counseling and health education: a survey of their knowledge and level of involvement in relation to type 2 diabetes mellitus**

Erku DA, Belachew SA, Mekuria AB, Haile KT, Gebresilassie BM, Teague HG, Ayele AA  
[Integrated Pharmacy Research and Practice 2017](#), 6:137-143  
 Published Date: **19 July 2017**

ORIGINAL RESEARCH 

**Addressing varenicline adherence through repackaging in a dose administration aid**

Drovandi AD, Robertson SG, Malau-Aduli BS, Teague PA, Glass BD  
[Integrated Pharmacy Research and Practice 2017](#), 6:131-135  
 Published Date: **23 June 2017**

METHODOLOGY 

**Defining pharmacy and its practice: a conceptual model for an international audience**

Scahill SL, Atif M, Babar ZU  
[Integrated Pharmacy Research and Practice 2017](#), 6:121-129  
 Published Date: **12 May 2017**

REVIEW 

**Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis**

Bridgeman MB  
[Integrated Pharmacy Research and Practice 2017](#), 6:109-119  
 Published Date: **4 May 2017**

Rafie S, Stone RH, Wilkinson TA, Borgelt LM, El-Ibiary SY, Ragland D

[Integrated Pharmacy Research and Practice 2017](#), 6:99-108

Published Date: **23 March 2017**

REVIEW 

#### Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting

Hadi MA, Neoh CF, Zin RM, Eirggall ME, Cheema E

[Integrated Pharmacy Research and Practice 2017](#), 6:91-98

Published Date: **22 March 2017**

REVIEW 

#### Review of community pharmacy services: what is being performed, and where are the opportunities for improvement?

Melton BL, Lai Z

[Integrated Pharmacy Research and Practice 2017](#), 6:79-89

Published Date: **6 March 2017**

ORIGINAL RESEARCH 

#### Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis

Saleem A, Masood I, Khan TM

[Integrated Pharmacy Research and Practice 2017](#), 6:71-77

Published Date: **17 February 2017**

REVIEW 

#### Preventing drug-related adverse events following hospital discharge: the role of the pharmacist

Nicholls J, MacKenzie C, Braund R

[Integrated Pharmacy Research and Practice 2017](#), 6:61-69

Published Date: **13 February 2017**

REVIEW 

#### Community pharmacy COPD services: what do researchers and policy makers need to know?

Twigg MJ, Wright DJ

[Integrated Pharmacy Research and Practice 2017](#), 6:53-59

Published Date: **7 February 2017**

ORIGINAL RESEARCH 

#### Prevalence of intravenous medication administration errors: a cross-sectional study

Fekadu T, Teweldemedhin M, Esrael E, Asgedom SW

[Integrated Pharmacy Research and Practice 2017](#), 6:47-51

Published Date: **31 January 2017**

REVIEW 

#### Role of the pharmacist in reducing healthcare costs: current insights

Dalton K, Byrne S

[Integrated Pharmacy Research and Practice 2017](#), 6:37-46

Published Date: **25 January 2017**

ORIGINAL RESEARCH 

#### Antihypertensive drug prescription patterns and their impact on outcome of blood pressure in Ethiopia: a hospital-based cross-sectional study

Abegaz TM, Tefera YG, Abebe TB

[Integrated Pharmacy Research and Practice 2017](#), 6:29-35

Published Date: **27 January 2017**

REVIEW 

#### The role of the pharmacist in the management of type 2 diabetes: current insights and future directions

Hughes JD, Wibowo Y, Sunderland B, Hoti K

[Integrated Pharmacy Research and Practice 2017](#), 6:15-27

Published Date: **16 January 2017**

ORIGINAL RESEARCH 

#### Benefit of hospital pharmacy intervention on the current status of dry powder inhaler technique in patients with asthma and COPD: a study from the Central Development Region, Nepal

Poudel RS, Piryani RM, Shrestha S, Prajapati A

[Integrated Pharmacy Research and Practice 2017](#), 6:7-13

Published Date: **20 December 2016**

REVIEW 

#### Abuse of over-the-counter medicines: a pharmacist's perspective

Sangiry SS, Bhansali AH, Bapat SS, Xu Q

[Integrated Pharmacy Research and Practice 2017](#), 6:1-6

Published Date: **19 December 2016**

[Contact Us](#) • [Privacy Policy](#) • [Associations & Partners](#) • [Testimonials](#) • [Terms & Conditions](#) • [Recommend this site](#) • [Top](#)

© Copyright 2022 • Dove Press Ltd • software development by maffey.com • Web Design by Adhesion

The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ("Informa") whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36